Empagliflozin 25 Mg & Linagliptin 5 Mg Tablets - Glimpazin-L 25 (100 Tablets)

Glimpazin-L 25 (Empagliflozin 25 mg + Linagliptin 5 mg Tablets):

Product Information- Brand Name: Glimpazin-L 25
- Active Ingredients:
    - Empagliflozin 25 mg
    - Linagliptin 5 mg
- Form: Tablets

Therapeutic Class

- Antidiabetic agent (combination)
- SGLT2 inhibitor + DPP-4 inhibitor

Indications

- Treatment of type 2 diabetes mellitus
- Improves glycemic control
- Reduces risk of cardiovascular events

Dosage and Administration

- Adult dose: 1 tablet once daily, in the morning
- Take with or without food

Mechanism of Action

- Empagliflozin:
    - Inhibits sodium-glucose cotransporter 2 (SGLT2)
    - Reduces glucose reabsorption in kidneys
    - Increases glucose excretion in urine
- Linagliptin:
    - Inhibits dipeptidyl peptidase-4 (DPP-4)
    - Increases incretin hormone levels
    - Enhances insulin secretion and reduces glucagon levels

Benefits

- Effective glycemic control
- Reduced risk of cardiovascular events
- Convenient once-daily dosing
- Combination therapy for improved efficacy

Side Effects

- Common:
    - Hypoglycemia (low blood sugar)
    - Urinary tract infections
    - Increased urination
    - Thirst
    - Headache
- Less common:
    - Allergic reactions
    - Increased risk of genital mycotic infections
    - Increased risk of acute kidney injury

Contraindications

- Hypersensitivity to empagliflozin or linagliptin
- Severe kidney impairment (eGFR <30 mL/min/1.73 m²)
- End-stage renal disease (ESRD)
- Dialysis
- Pregnancy and lactation (caution advised)

Precautions

- Monitor blood sugar, kidney function, and liver enzymes regularly
- Inform doctor about concomitant medications
- Caution in patients with:
    - Renal or hepatic impairment
    - History of pancreatitis
    - History of hypersensitivity reactions